title: A special article following the relicence of aprotinin injection in Europe.
authors.affiliation: Cardiothoracic anaesthesia, critical care and pain, Royal Brompton and Harefield NHS foundation trust, Harefield hospital, Harefield, UK. Electronic address: d.royston@rbht.nhs.uk.
authors.forename: David
authors.initials: D
authors.lastname: Royston
authors.affiliation: Department of anesthesiology, Ghent University, Ghent university hospital, De Pintelaan 185, 9000 Ghent, Belgium.
authors.forename: Stefan
authors.initials: S
authors.lastname: De Hert
authors.affiliation: Thoraxkliniken/Department of cardiothoracic surgery & anesthesiology, Karolinska institutet, Karolinska university hospital, 17176 Stockholm, Sweden.
authors.forename: Jan
authors.initials: J
authors.lastname: van der Linden
authors.affiliation: Department of anaesthesia and critical care II, CHU de Bordeaux, 33600 Pessac, France; INSERM, biology of cardiovascular diseases, U1034, university Bordeaux, 33600 Pessac, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Ouattara
authors.affiliation: Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
authors.forename: Kai
authors.initials: K
authors.lastname: Zacharowski
mesh_terms: D007611:Aprotinin / Q000009:adverse effects* / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures / Q000379:methods; D005060:Europe; D006490:Hemostatics / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007430:Intraoperative Care / Q000379:methods; D007880:Legislation, Drug; D008004:Licensure
chemical_list: D006490:Hemostatics; D007611:Aprotinin
keywords: Aprotinin; Benefit-Risk analysis; Conditions of use; Nordic Aprotinin Patient Registry (NAPaR); Relicense